Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 73.1%

Neg 0% Neu 0% Pos 73.1%

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $60.